Table 3.
Treatment details, intensive care needs, and outcome of children with dilated cardiomyopathy associated with vitamin D deficiency
| Characteristics | Total cases (n = 14) |
|---|---|
| Intravenous calcium infusion, n (%) | 5 (35.7) |
| Vitamin D supplementation, n (%) | 14 (100) |
| Parenteral, n (%) | 8 (57.1) |
| Oral, n (%) | 6 (42.9) |
| Activated vitamin D, n (%) | 5 (35.7) |
| Oxygen therapy, n (%) | 14 (100) |
| HFNC, n (%) | 2 (14) |
| Invasive mechanical ventilation, n (%) | 5 (35.7) |
| Duration of mechanical ventilation (hours), median (IQR) | 41 (27–107) |
| Vasoactive drug requirement, n (%) | 8 (57.1) |
| Milrinone | 8 (57.1) |
| Epinephrine | 4 (28.6) |
| Dobutamine | 3 (21.4) |
| Required > 1 vasoactive drugs, n (%) | 5 (35.7) |
| Renal replacement therapy, n (%) | 0 (0) |
| PICU mortality, n (%) | 0 (0) |
| Length of PICU stay (hours), median (IQR) | 76 (31–98) |
| Length of hospital stay (days), median, (IQR) | 6 (4.7–10) |
| Follow-up (n = 10) | |
| Long term follow-up (months), median (IQR) | 10 (7–58) |
| Left ventricular ejection fraction at last follow-up, median (IQR) | 55 (55–60) |